2025年3月31日，由安科生物、药明生物、维梧资本等作为基石投资者的维升药业在港交所成为IPO。截止到发稿期，该公司股价较发行价（68.80港元/股）微跌破发。IPO破发背后，折射出港股市场对创新药估值逻辑的重新校准。其核心价值在于三款“First-in-Class”产品覆盖的蓝海市场（儿童生长激素缺乏症、软骨发育不全、甲状旁腺功能减退症），但破发风险点在于：生长激素集采倒计时：安徽牵头全国...
Source Link2025年3月31日，由安科生物、药明生物、维梧资本等作为基石投资者的维升药业在港交所成为IPO。截止到发稿期，该公司股价较发行价（68.80港元/股）微跌破发。IPO破发背后，折射出港股市场对创新药估值逻辑的重新校准。其核心价值在于三款“First-in-Class”产品覆盖的蓝海市场（儿童生长激素缺乏症、软骨发育不全、甲状旁腺功能减退症），但破发风险点在于：生长激素集采倒计时：安徽牵头全国...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.